Company intelligence / Profile preview

Discovery Therapeutics

Cleveland, Ohio, United Statesdiscothera.com ↗

Ownership: Private
Development stage: Phase 3

Overview

DTC received a "Study May Proceed" letter from the FDA in Q1 2024 to initiate a Phase 3 clinical trial of intralesional rhEGF for the treatment of diabetic foot ulcers. The trial will be randomized, double-blind, and placebo-controlled, focusing on severe ulcers classified as Wagner's grades 3 and 4, University of Texas grades 2 and 3, and Wound/Ischemia/Foot Infection stages 3 and 4[3].

Therapeutic areas: Endocrinology
Modalities: Biologics (recombinant human Epidermal Growth Factor/rhEGF)
Industry: Biotech

Drug pipeline

1 asset

Heberprot-P

Phase 3

Indications: Diabetic foot ulcers

Partnerships

Exclusive collaboration agreement for developing rhEGF for the US marketExclusive license agreement to market Heberprot-P® in the United States and other territories[3]

Beyond the preview

Go deeper on Discovery Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Discovery Therapeutics.

Explore the full profile